Amneal Pharmaceuticals, Inc. Press Releases https://investors.amneal.com/generated by Q4Wed, 24 Jun 2026 20:36:38 -0400Copyright Q4 Inc. All rights reserved.Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Diseasec2bedb01-26b7-47a7-8273-524681a6a026https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-Announces-Full-Study-Population-Interim-Phase-4-ELEVATE-PD-Results-Reinforcing-Previously-Reported-Benefits-of-CREXONT-in-Parkinsons-Disease/default.aspxFri, 05 Jun 2026 08:00:00 -0400Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution65ad83a8-eed6-4d17-a029-e0d876d8b128https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-Announces-U-S--FDA-Approval-of-Romidepsin-Injection-Solution/default.aspxThu, 04 Jun 2026 08:00:00 -0400Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026e0cfbcd8-b65f-45d9-8fd6-9ac6beb7884fhttps://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-to-Participate-in-Goldman-Sachs-47th-Annual-Global-Healthcare-Conference-2026/default.aspxMon, 01 Jun 2026 08:00:00 -0400Amneal Reports First Quarter 2026 Financial Results6e266563-2872-400b-9318-ed88bb8d65a3https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-Reports-First-Quarter-2026-Financial-Results/default.aspxThu, 07 May 2026 16:01:00 -0400Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance8aa03646-b6d2-40b8-b9a3-7362d4c9d385https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-Agrees-to-Acquire-Kashiv-BioSciences-to-Create-Global-Biosimilar-Leader-Reports-Strong-Preliminary-First-Quarter-2026-Financial-Results-and-Raises-FY2026-Standalone-Guidance/default.aspxWed, 22 Apr 2026 06:00:00 -0400Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®ea09d207-66a9-4814-bf57-e333d745d1d1https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-Announces-Additional-Positive-Interim-Phase-4-ELEVATE-PD-Results-with-CREXONT-for-Parkinsons-Disease-Including-Over-3-More-Hours-of-Daily-Good-On-Time-When-Switching-from-RYTARY/default.aspxMon, 20 Apr 2026 08:00:00 -0400Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.b1da012d-a56b-4c45-9b3a-63fe111af3d4https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-Launches-First-Two-Respiratory-Metered-Dose-Inhalation-Products-in-the-U-S-/default.aspxTue, 14 Apr 2026 08:00:00 -0400Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%e7dd1712-4deb-46a4-8e83-348db3f49b50https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-Launches-Bimatoprost-Ophthalmic-Solution-0-01/default.aspxThu, 09 Apr 2026 08:00:00 -0400Amneal to Report First Quarter 2026 Results on May 1, 2026a5470c3c-0f16-4793-b3d4-ee5b003d6355https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-to-Report-First-Quarter-2026-Results-on-May-1-2026/default.aspxTue, 07 Apr 2026 16:01:00 -0400Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Montha3e8861d-dcfd-4b81-bd52-0da79ce6f9c3https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-Announces-2-Million-Donation-to-Support-Patient-Access-to-Essential-Medicines-During-Parkinsons-Awareness-Month/default.aspxTue, 07 Apr 2026 08:00:00 -0400